Nanoparticle Di-adjuvant is a specialized cholesterol and phospholipid-based cage-like nanoparticle adjuvant system formulated with the saponin QS-7 component and saponin QS-21 component. Designed for advanced vaccine development and immunization research, this di-adjuvant is positioned for use in malaria vaccine, adult influenza vaccine, and cancer vaccine applications. Its nanoparticle architecture is intended to support next-generation antigen delivery and immune response enhancement in controlled research and GMP-grade environments. This product is specifically suited for B2B buyers in the biopharmaceutical, vaccine R&D, and life sciences sectors that require high-performance adjuvant components for experimental and manufacturing workflows. The cage-like nanoparticle structure provides a sophisticated formulation platform for downstream vaccine formulation studies. Available in Research grade and GMP grade quality levels, it is aligned with both laboratory-scale development and regulated production needs. For buyers searching for a saponin-based nanoparticle adjuvant, QS-7/QS-21 adjuvant system, or cholesterol-phospholipid vaccine adjuvant, this product offers a highly targeted solution. It is not a general-purpose chemical; it is a specialized vaccine adjuvant ingredient intended for advanced immunology applications.

*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.